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Background: High concentrations of plasmatic IgE have been related to distinct systemic inflammatory conditions
that frequently predispose individuals to hypersensitivity reactions. Although effects of IgE have been suggested to
relay on the low-intensity activation of distinct effector elements of the immune system, such as mast cells (MC),
experimental evidence on the role of IgE-induced production of inflammatory mediators on specific pathologies is
scarce. MC are an important component in tumor microenvironment where they seem to secrete a number of
immunomodulatory and angiogenic mediators, such as the Vascular Endothelial Growth Factor (VEGF) by not well-
described mechanisms. In this work, we investigated the effect of monomeric IgE (in the absence of antigen) on
the production of VEGF in MC, analyzed if monomeric IgE could exacerbate the pro-tumorigenic properties of that
cell type and characterized some of the molecular mechanisms behind the effects of IgE on VEGF production and
tumor growth.
Methods: For in vitro studies, murine bone marrow-derived mast cells (BMMCs) were used. Pharmacological
inhibitors and phosphorylation of key elements controlling VEGF secretion and protein translation were used to
characterize the mechanism of VEGF production triggered by IgE.
In vivo, the effect of a single i.v. administration of monomeric IgE on B16 melanoma tumor weight, intratumoral
blood vessel formation and tumor-associated MC was assessed in four groups of mice: MC-proficient (WT),
MC-deficient (Wsh), Wsh reconstituted with MC derived from WT mice (Wsh Rec WT) and Wsh reconstituted
with MC derived from Fyn −/− mice (Wsh Rec Fyn −/−).
Results: Monomeric IgE induced VEGF secretion through a Fyn kinase-dependent mechanism and modulated de
novo protein synthesis modifying the activity of the translational regulator 4E-BP1 in BMMCs. In vivo, monomeric IgE
increased melanoma tumor growth, peritumoral MC and blood vessel numbers in WT but not in Wsh mice. The
positive effects of IgE on melanoma tumor growth were reproduced after reconstitution of Wsh mice with WT but
not with Fyn −/− BMMCs.
Conclusion: Our data suggest that monomeric IgE, in the absence of antigen, induces VEGF production in MC and
in vivo contributes to melanoma tumor growth through a Fyn kinase-dependent mechanism.
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High concentrations of plasmatic IgE are related to a
number of systemic inflammatory conditions [1] and re-
cent evidence has lead to propose that inflammation
predisposes individuals to certain types of cancer [2].
Some data indicate that underlying infections and in-
flammatory responses are linked from 15 to 20% of all
deaths due to cancer worldwide [3].
Mast cells (MCs) are central players in allergic reac-
tions and also constitute a well documented component
of tumor microenvironment [4,5]. The pleiotropic ac-
tions of this cell type are associated with its remarkable
capacity of synthesis and secretion of diverse lipid medi-
ators after IgE/antigen stimulation. Proteases, cytokines,
chemokines and growth factors (i.e. Tumor Necrosis
Factor, TNF; Interleukin (IL)-1,2,3,4,6, and 13, and the
Vascular Endothelial Growth Factor, VEGF) secreted by
MC have been proposed to modulate tissue remodeling,
immune response and angiogenesis [5,6].
The best characterized stimulus for MC activation is
the crosslinking of the high affinity IgE receptor (FcεRI),
which occurs after the interaction of IgE bound to the
receptor with specific antigens [4]. After FcεRI trigger-
ing, two Src-family kinases (Lyn and Fyn) are activated
to initiate different intracellular events leading to cyto-
kine production [7,8]. It has been well documented that
Lyn phosphorylates key sites on ITAM motifs of the re-
ceptor, initiating signaling and activating mechanisms of
negative control of signaling [9], whereas Fyn kinase has
a positive regulatory role for the activation of PI3K and
leukotriene production [10].
The initial binding of monomeric IgE to the receptor
was considered for long time as a “sensitization” event for
late antigen-dependent stimulation. Recent in vitro studies
have shown, however, that non-specific IgE, in the absence
of antigen, is able to modify MC secretory profile in dis-
tinct cell preparations and cell lines. Those changes, pro-
duced by IgEs with no relevant recognition for specific
antigens, have been hypothesized to be relevant to the
initiation of local inflammatory reactions, especially in
humans with high levels of circulating IgE, like atopic indi-
viduals [1,11]. However, to date, the effect of monomeric
IgE on the production of angiogenic factors such as VEGF
and its consequences on inflammation-related angiogen-
esis is not well-described.
MC activation is closely related to tumor growth [12,13].
Specifically, in human and murine melanoma biopsies, in-
creased numbers of MC correlate with a high microvascu-
lar density in tumors and poor prognosis [14]. In addition,
a strong significant correlation has been found between the
number of VEGF-positive peritumoral MC, microvessel
density and aggressive melanoma [15]. The mechanisms of
MC activation that could contribute to the secretion of
pro-angiogenic factors have not been fully described.The objective of this work was threefold 1) to test if
monomeric IgE (in the absence of antigen) could induce
the production of VEGF in MC in vitro; 2) to analyze if
monomeric IgE could exacerbate the pro-tumorigenic
properties of this cell type in vivo; and 3) to investigate
some of the molecular mechanisms underlying the ef-
fects of IgE on VEGF production and tumor growth.
Results
Monomeric IgE induces VEGF secretion in MC through a
mechanism that requires de novo synthesis, tetanus
toxin-sensitive VAMPs and the activity of Fyn kinase
Production of angiogenic factors by MC has been shown
to occur few hours after different stimuli, such as hyp-
oxia, antigen or PMA [16,17]. To investigate if mono-
meric IgE in the absence of any antigen could induce
VEGF secretion in this cell type, two million BMMCs
were incubated with a monoclonal anti-DNP IgE (1000
ng/ml) for eight hours at 37°C in BMMC media. Super-
natants were then collected and the amount of secreted
VEGF was determined by ELISA. The addition of IgE to
MC induced a significant secretion of VEGF (53.77 ±
2.15 pg/ml in basal conditions vs 117.16 ± 5.45 pg/ml on
IgE-stimulated cells; Figure 1A). To gain insight on the
mechanism involved in IgE-induced VEGF production,
cells were pre-treated with different pharmacological
inhibitors 15 minutes before the addition of IgE and
secreted VEGF was measured. VEGF secretion was sen-
sitive to actinomycin D (ActD) and brefeldin A (BFA),
indicating that de novo transcription and transport from
endoplasmic reticulum to the Golgi apparatus [18] was
needed for IgE effects to occur. VEGF production was
also affected by tetanus toxin (TTx), which inhibits se-
cretion mediated by toxin-sensitive VAMPs (VAMP-1
and −2) [19], and PP2, that inhibits Src family kinases
(Figure 1A).
Two main Src family kinases modulate mediator secre-
tion from MCs. Lyn and Fyn kinases have been shown to
be involved in early signaling after FcεRI crosslinking,
leading to the activation of downstream pathways regulat-
ing pro-inflammatory cytokine production [7]. In order to
test if one of them could be involved in IgE-induced VEGF
secretion in BMMC, cells from WT, Lyn −/− and Fyn −/−
mice were generated and stimulated with different con-
centrations of monomeric IgE (Figure 1B). WT BMMCs
reached maximal VEGF secretion after the incubation
with 1000 ng/million cells while BMMCS generated from
Lyn −/− mice did not show an important difference when
compared to WT cells. However, BMMCs derived from
Fyn −/− mice showed an important defect on IgE-induced
VEGF production, since the maximal amount of secreted
VEGF in Fyn −/− cells was significantly lower than in WT
cells (Figure 1B). We then characterized the time course
of VEGF secretion stimulated by IgE in WT and Fyn −/−
Figure 1 Monomeric IgE induces secretion of VEGF in BMMCs
through a mechanism that requires Fyn. (A) Pharmacological
characterization of IgE-induced VEGF secretion in MC. Two million
BMMCs were pre-incubated with vehicle, Actinomicyn D (Act D; 5
μg/ml), Brefeldin A (BFA; 5μg/ml), Tetanus toxin (TTx; 10 ng/ml) and
PP2 (10 μM) for 15 min in BMMC media. Then, cells were stimulated
with 1000 ng of IgE for 8 h at 37°C. VEGF in cell supernatants was
quantified by ELISA. (B) Role of different Src family kinases on IgE-
induced VEGF secretion in MC. Two million BMMCs derived from
WT, Fyn −/− and Lyn −/− mice were incubated with different
amounts of IgE at 37°C for eight hours. Supernatants were collected
and VEGF was determined by ELISA. (C) Time-course of VEGF
secretion after the addition of IgE. Two million BMMCs were
incubated in cell culture media containing 1000 ng/million cells of
IgE at 37°C and supernatants were collected at different times after
stimulation. VEGF was determined by ELISA. All results are shown as
the mean ± SEM (n = 3-12). *, P < 0.05 compared with basal or time
0, &, P < 0.05 compared with IgE treatment, #, P < 0.05 compared to
WT. One way ANOVA post hoc Student-Newman-Keuls (A). Two way
ANOVA post hoc Student-Newman-Keuls (B and C).
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two hours after stimulation and the maximal amount was
reached after eight to twelve hours of stimulation in both
cell types. However, Fyn −/− BMMCs did not secrete as
much VEGF as WT cells even at longer incubation times
(Figure 1C).
Monomeric IgE in the absence of antigen induces
intracellular VEGF accumulation in a Fyn kinase-
dependent fashion
In order to investigate the role of Fyn kinase in the IgE-
dependent VEGF synthesis, BMMCs derived from WT
or Fyn −/− mice were incubated at 37°C in the presence
of vehicle or IgE (1000 ng/ml) for 8 hours. Cells were
collected using a cytospin centrifuge and processed to
detect VEGF by fluorescent immunostaining. Figures 2A
and B show that low VEGF positive signal was observed
in WT BMMCs and IgE addition increased intracellular
VEGF. In contrast, VEGF immunoreactivity was signifi-
cantly lower in Fyn −/− BMMCs in both basal and IgE-
stimulated conditions.
In order to investigate if the absence of Fyn could lead
to alterations on IgE-dependent VEGF mRNA synthesis,
we analyzed VEGF mRNA content by RT-PCR in WT and
Fyn −/− BMMCs after IgE stimulation. Optimal condi-
tions for amplification of VEGF and GAPDH (control)
were experimentally determined in our cell system (see
Methods section). VEGF164 mRNA, the predominant iso-
form in different cell systems including MC [13], was in-
creased in WT BMMCs after IgE addition and the same
effect was observed in Fyn −/− cells. Interestingly, Fyn −/−
BMMCs showed slightly higher amounts of VEGF mRNA
than WT BMMCs in the absence of any stimulus and also
one hour after IgE addition (Figure 2C-D). Together, these
results strongly suggested that Fyn kinase could be









Figure 2 IgE-induced VEGF protein but not mRNA accumulation is affected in Fyn −/− BMMCs. (A and B) Intracellular VEGF accumulation
after IgE treatment of MC. Two million WT and Fyn −/− BMMCs were stimulated with 1000 ng of IgE for eight h at 37°C. Cells were collected in a
cytospin and slides were incubated in the presence of an anti-VEGF antibody (red) and DAPI (blue). Samples were processed to detect
intracellular VEGF by confocal microscopy. A representative picture obtained from at least three independent experiments is shown. Scale
bar = 10 μm. Mean fluorescence intensity values of VEGF signal obtained from experiments shown in A (n = 3) are represented in B. *, P < 0.0001
compared with IgE 0 ng; &, P < 0.001 compared with WT. Two way ANOVA post hoc Student-Newman-Keuls. (C and D) VEGF mRNA expression
in IgE-stimulated MC. Total mRNA was purified from WT or Fyn −/− BMMCs treated with 1000 ng IgE and VEGF164 mRNA was amplified by
RT-PCR. GAPDH amplification is shown as a control. Densitometric quantification of VEGF164 mRNA (n = 2) is shown in D.
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production.
IgE alters MC protein translation through the Fyn-
dependent 4E-BP1 dephosphorylation
To test the hypothesis that IgE-induced VEGF protein
translation could be defective in the absence of Fyn, we
evaluated whether VEGF synthesis in Fyn −/− cells could
be more sensitive to the protein synthesis inhibitor cy-
cloheximide (CHX) than in WT BMMCs. We found that
CXH pre-treatment provoked a decrease on VEGF pro-
duction in both cell types, but Fyn−/− BMMCs showed
an increased sensitivity to this inhibitor (Figure 3A). The
main difference was detected at concentrations of 1 μM
of CHX, where normalized VEGF production wasinhibited by 26.53% of the maximal release in WT cells,
compared to 52.49% in Fyn −/− BMMCs.
It has been shown that VEGF synthesis under different
stressful conditions (such as hypoxia) depends on the
rapid modification of protein translation machinery [20].
In those circumstances, the normal 5′cap-dependent
translation is stopped and internal ribosome entry sites
(IRES)-dependent translation proceeds on VEGF mRNA
[20]. Those adjustments on the translational apparatus
can be followed by changes on the phosphorylation of
the ribosomal protein S6 (S6) and the dephosphorylation
of the eukaryotic initiation factor 4E binding protein 1
(4E-BP1) [21,22]. To investigate if IgE could induce a
stressful condition similar to hypoxia in MC leading to
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Figure 3 Fyn is involved in IgE-induced VEGF protein translation and in IRES-dependent translation. (A) IgE-induced VEGF synthesis is
sensitive to cicloheximide. Two million BMMCs were pre-incubated with cycloheximide (CHX) for 15 min in cell culture media at 37°C. Then, cells
were stimulated with 1000 ng of IgE for eight hours. VEGF was determined in cell supernatants. Results are shown as the mean ± SEM (n = 3). *,
P < 0.05 compared with basal, #, P < 0.05 compared with IgE-treated cells. &, P < 0.05 compared with WT cells. Two way ANOVA post hoc
Student-Newman-Keuls. (B) Effect of IgE on the activation of translational regulators. Two million BMMCs were stimulated with 1000 ng of IgE for
0, 15, 30 and 60 min in cell culture media. Western blot analysis of S6 and 4E-BP1 protein phosphorylation induced by IgE in MC. β-actin was
used as a loading control. Samples were normalized to their respective β-actin loading control and data are expressed as arbitrary units.
(C) Quantification of S6 and 4E-BP1 phosphorylation in WT BMMCs. (D) Quantification of S6 and 4E-BP1 phosphorylation in Fyn −/− BMMCs.
Mean ± SEM (n = 3). *, P < 0.05 compared with 0 ng of IgE; &, P < 0.05 compared with WT. Two way ANOVA post hoc Student-Newman-Keuls.
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Fyn −/− BMMCs stimulated with IgE.
Figure 3B shows that IgE addition to BMMCs induce a
rapid phosphorylation of S6 and dephosphorylation of
4E-BP1 in WT cells. In contrast IgE-dependent, dephos-
phorylation of 4E-BP1 was not detected in the absence
of Fyn. Quantitative analysis of western blots performed
for Figure 3B is presented on Figure 3C-D. Optical dens-
ity values of each specific band were normalized with
those obtained from actin in the same membrane (see
Material and Methods section). Results show that IgE is
able to induce changes on the translational machinery of
MC, promoting IRES-dependent translation in a Fyn-
dependent manner.
Non-specific monomeric IgE increases B16 melanoma
tumor growth in a MC-dependent fashion
In order to evaluate the effect of IgE on the secretion of
VEGF in MC and the role of Fyn kinase in that process
in vivo, we took advantage of the well-recognized role of
MC and VEGF on the development of B16 melanoma
tumor [15,23]. A number of experiments have shownthat MC have a positive effect on murine melanoma
angiogenesis and tumor growth [23,24]. For instance,
MC-deficient mice (Wv strain) are unable to generate
angiogenesis of B16 melanoma tumors and the reconsti-
tution of those animals with WT BMMCs leads to the
restoration of tumor development [23]. The number of
VEGF positive MC located in the peritumoral area has
been found to correlate with increased angiogenesis and
poor prognosis of melanoma [15].
We started defining the amount of IgE that could be
administered in mice to analyze its effect on melanoma
tumor growth. We decided to utilize a dose of IgE that
could give a measurable parameter of MC and basophil
activation. Passive anaphylactic reactions have been
shown to depend on MC activity when initiated with an
specific IgE and triggered with the corresponding anti-
gen [25,26]. Exogenous IgE occupies free FcεRI receptors
on immune cells and those can be crosslinked adminis-
trating the antigen to which IgE was synthesized [27].
We determined the concentration of IgE needed for
maximal activation of passive anaphylactic reaction in
C57BL/6J mice. Monomeric IgE directed against DNP-
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four hours later, antigen was i.v. injected in the presence
of Evans blue dye. Twenty minutes after antigen adminis-
tration, limbs were removed and dye extravasation was
measured. As can be observed in Figure 4, the optimal IgE
dose to obtain maximal anaphylactic response was 750 ng
per mouse and the effect of IgE was long-lasting, since
antigen-specific anaphylactic reaction was observed in the
limbs even four weeks after a single IgE administration.
To evaluate the effect of IgE on melanoma tumor
growth, C57BL6/J (WT) mice were treated with a single
i.v. administration of saline or monomeric IgE (750 ng/
mouse) and twenty four hours later, mice were subcuta-
neously (s.c.) inoculated with B16 melanoma cells in one
ear pinna and generated tumors were removed after four
weeks. Tumors obtained from IgE-treated mice (+IgE)
were larger than those obtained from saline-treated mice
(−IgE) (Figure 5A). Histopathologic analysis of tumor
sections utilizing hematoxilin-eosin (H&E) and toluidine
blue (TB) stains showed that those obtained from IgE-
treated mice presented significantly higher numbers of
blood vessels inside the tumor and MC in the
peritumoral area (Figure 5B-D). The role of VEGF on
melanoma tumor growth was verified in our system
by the use of the neutralizing anti-VEGF antibody
Bevacizumab (Beva; Figure 5E). As expected, administra-
tion of Beva (10 mg/kg) diminished tumor size. Remark-
ably, the effect of IgE on tumor growth was prevented
by the administration of that agent.
When B16 melanoma cells were inoculated in MC-
deficient mice (Wsh), the size of the tumors after 28
days was significantly lower than the observed in WTFigure 4 IgE causes sustained increase on specific anaphylactic reacti
administered with discrete amounts of monomeric IgE directed against DN
blue dye was i.v. injected and twenty minutes later, a passive cutaneous an
nm of the extravasation dye in the limbs. Results are shown as the mean ±
anaphylaxis after a single administration of IgE. C57BL/6J mice were i.v. adm
antigen was i.v. injected in Evans blue dye at days 1, 7, 14, 21 and 28 after
anaphylaxis assay was performed. Results are shown as the mean ± SEM (nmice (Figure 6A-B). As expected, normal tumor size
was recovered after the reconstitution of Wsh animals
with BMMCs derived from WT mice (Wsh Rec WT).
Interestingly, monomeric IgE importantly increased the
size of melanoma tumors on WT and Wsh Rec WT
mice but this effect was not observed in Wsh animals
treated with IgE. The effect of IgE on melanoma tumor
growth positively correlated with the capacity of IgE to
induce anaphylactic reactions, since Evans blue extrava-
sation in Wsh Rec WT mice was similar to the observed
in C57BL6/J mice under the same treatment (data
not shown).
Histological analysis of biopsies of Wsh and Wsh Rec
WT-derived tumors, in the presence or absence of IgE,
was performed by staining slides with H&E and TB dyes.
The number of blood vessels and peritumoral MC was
significantly higher in Wsh Rec WT than in Wsh mice
(Figure 6 C-D).Fyn kinase in MC is required for IgE-induced melanoma
tumor growth
To investigate if Fyn kinase in MC could be involved in
IgE-induced melanoma growth and angiogenesis, Wsh
mice were reconstituted with BMMCs from Fyn −/−
mice (Wsh Rec Fyn−/−). IgE-dependent tumor growth
was significantly impaired in mice reconstituted with
Fyn−/− BMMCs compared to mice reconstituted with
WT cells (Figure 7A-B). A decreased number of blood
vessels and MC were observed in tumor biopsies
obtained from Wsh Rec Fyn−/− mice compared to those
obtained from Wsh Rec WT animals (Figure 7C).on. (A) Effect of IgE on anaphylactic reaction. C57BL/6J mice were i.v.
P-HSA. Twenty four hours later, antigen (100 μg) in 100 μl of Evans
aphylaxis assay was performed. A620 represents the absorbance at 620
SEM (n = 4-10). (B) Time-course of specific passive cutaneous
inistered with monomeric IgE directed against DNP-HSA (750 ng),
sensitization with IgE. Twenty minutes later, a passive cutaneous
= 7-10). *, P < 0.05 versus 0 ng of IgE; &, P < 0.05 versus vehicle.
Figure 5 IgE causes increased melanoma tumor growth. (A) Effect of IgE on B16 melanoma tumor weight in C57BL/6J mice. Animals were
treated with a single i.v. administration of saline (−IgE) or monoclonal anti-DNP IgE (750 ng/mouse; +IgE). Twenty four hours later, mice were s.c.
inoculated with B16 melanoma cells (+B16) in one ear pinna and tumor weight was determined after four weeks of inoculation. Upper panel, a
representative picture of vehicle or IgE-treated mice and vehicle or B16 cells-treated ear pinna. Lower panel, quantification of tumor weight.
Results are shown as the mean ± SEM (n = 11-12). *, P < 0.05 versus + IgE mice. (B) Histological analysis of tissue biopsies. Ear pinna sections (2.5
μm) were stained with H&E (upper pictures) and TB (lower pictures). Blood vessels are indicated by arrows and MC by arrowheads. Photos are
representative images from distinct mice (n = 2-4). Scale bar = 20 μm. (C) Quantification of MC by TB staining. Data are expressed as mean ± SEM
from two sections per mouse, (n = 2-4). *, P < 0.05 versus –IgE + BL6. (D) quantification of blood vessels per ear pinna in tissue sections. Mean ±
SEM (n = 3). *, P < 0.05 versus –IgE + BL6. (E) Effect of Bevacizumab on the IgE-dependent effects on melanoma tumor growth. Mice were treated
with Bevacizumab (Beva; 10 mg/kg; s.c.) biweekly, starting 24 h after inoculation of melanoma cells. Ear pinna were removed and tumors were
measured as in panel A. Data are expressed as the mean ± SEM (n = 4-11). *, P < 0.05 versus –IgE + BL6.
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A possible link between inflammation and cancer was
first proposed in the nineteenth century, based on obser-
vations that tumors often arose at sites of chronic in-
flammation and that inflammatory cells were present in
biopsies from tumors [3]. Since then, the critical rela-
tionship between inflammation and cancer development
has been under investigation [2]. Controversial results
have been obtained from studies that analyze the rela-
tionship between allergic inflammation and cancer. It
has been found that allergies increase the risk of bladder
cancer, lymphoma, myeloma, and prostate cancer. How-
ever, a decreased risk has been reported among allergiesand glioma, colorectal cancer, cancer of the larynx, non-
Hodgkin lymphoma, cancer of the esophagus, oral can-
cer, pancreatic cancer, stomach cancer, and uterine body
cancer [28].
In this paper we show that monomeric IgE (with irrele-
vant capacity of tumor recognition and in the absence of
antigen) induces VEGF production in isolated MC
through a Fyn kinase-dependent mechanism, and this ex-
acerbates pro-tumorigenic properties of this particular cell
type in vivo.
Our results show, for the first time, that nonspecific
monomeric IgE promotes the synthesis of pro-angiogenic
factors modulating the protein translation system in MC.
Figure 6 IgE improves the pro-tumorigenic properties of MC. (A and B) Participation of MC on IgE-induced melanoma tumor growth.
C57BL6/J (WT), Wsh and Wsh Rec WT mice were treated with a single i.v. administration of saline (−IgE) or monoclonal anti-DNP IgE (750 ng/
mouse; +IgE). Twenty four hours later, mice were s.c. inoculated with B16 melanoma cells (+B16) in one ear pinna and tumor weight was
determined four weeks after inoculation. Representative pictures of tumors from WT, Wsh and Wsh Rec WT mice after four weeks of inoculation
are shown in A. Mean tumor weight of WT, Wsh and Wsh Rec WT mice. Mean ± SEM (n = 7-12). *, P < 0.05 versus IgE-treated mice; #, P < 0.05
versus WT IgE-treated mice; &, P < 0.05 versus Wsh IgE-treated mice. (C) Histological analysis of tissue biopsies. Ear pinna sections (2.5 μm) were
stained with H&E and TB. Blood vessels are indicated by arrows and MC by arrowheads. Pictures are representative images (n = 2-3). Scale bar =
20 μm. (D) Quantification of blood vessels in ear pinna from treated animals. Mean ± SEM (n = 3). *, P < 0.05 versus WT-IgE + B16; α, P < 0.001
versus WT-IgE + B16; β, P < 0.001 versus WT + IgE + B16; λ, P < 0.05 versus WT-IgE + B16; δ, P < 0.001 versus Wsh-IgE + B16; ø, P < 0.001 versus
Wsh Rec WT-IgE + B16; Ω, P < 0.001 versus Wsh + IgE + B16; Ψ, P < 0.01 versus WT + IgE + B16; ∑, P < 0.05 versus Wsh-IgE + B16.
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been shown to activate MC leading to the production of
inflammatory mediators [29-31] we were able to detect
VEGF production in lower concentrations of IgE, indicat-
ing that secretion of this pro-angiogenic factor could
occur in the absence of extensive FcεRI aggregation.
Pharmacological characterization of IgE-induced VEGF
production indicates that this factor is transported from
ER-to-Golgi and is secreted in vesicles decorated with
TTx-sensitive VAMPs. This mechanism resembles the
reported pathway of hypoxia-induced VEGF secretion
in BMMCs [16]. The observed pharmacological profile
contrasts with that leading to pre-formed mediators
exocytosis, such as β-hexosaminidase [16], which re-
quires TTx-insensitive VAMPS and is resistant to
brefeldin treatment. Our data suggest that monomericIgE and hypoxia could share some common effectors
that participate in cytokine production, since both stimuli
induce VEGF release without extensive MC degranulation
tested by β-hexosaminidase activity in the supernatant of
IgE-treated cells (data not shown).
The modifications of the translational apparatus associ-
ated to VEGF production were analyzed and it was found
that monomeric IgE induced dephosphorylation of 4E-BP1
in WT MC, suggesting an increase on IRES-dependent
protein translation. In contrast, 4E-BP1 dephosphorylation
was not observable in the absence of Fyn, where even an
increase on 4E-BP1 phosphorylation was detected after
IgE treatment. Our data show for the first time that mono-
meric IgE causes changes on the translational machinery
of MC, favoring IRES-dependent protein translation, in
a Fyn dependent-manner. Since the IRES-dependent
Figure 7 Fyn kinase facilitates MC-mediated melanoma tumor growth. (A and B) Role of Fyn kinase in MC on IgE-induced melanoma tumor
growth. Wsh Rec WT and Wsh Rec Fyn −/− mice were treated with a single i.v. administration of saline (−IgE) or monoclonal anti-DNP IgE (750
ng/mouse; +IgE). Twenty four hours later, mice were s.c. inoculated with B16 melanoma cells (+B16) in one ear pinna and tumor weight was
determined after four weeks of inoculation. Representative pictures of tumors from Wsh Rec WT and Wsh Rec Fyn−/− mice after four weeks of
inoculation are shown in A. Results are shown as the mean tumor weight from Wsh Rec WT and Wsh Rec Fyn−/− mice. Mean ± SEM (n = 3-11).
*, P < 0.05 compared with IgE-treated mice. #, P < 0.05 compared with Wsh Rec WT IgE-treated mice. (C) Histological analysis of tissue biopsies.
Ear pinna sections (2.5 μm) were stained with H&E and TB. Blood vessels are indicated by arrows and MC by arrowheads. Pictures are
representative images (n = 3-4). Scale bar = 20 μm. (D) Quantification of blood vessels in ear pinna from treated mice. Mean ± SEM (n = 3). #,
P < 0.05 versus Wsh Rec WT + IgE + B16; ø, P < 0.001 versus Wsh Rec WT-IgE + B16; Δ, P < 0.01 versus Wsh Rec WT + IgE + B16.
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during hypoxic conditions [20], it is possible to speculate
that IgE could induce some signaling pathways activated
also by hypoxia. Current experiments in our laboratory
have been designed to determine if monomeric IgE acti-
vates similar pathways to hypoxia in MC.
When IgE was administered in vivo, an increased size
of melanoma tumors was observed in WT and in Wsh-
reconstituted mice. To our knowledge, this is the first
report showing that non-specific IgE promotes melan-
oma tumor growth and angiogenesis in a MC-dependent
fashion. Loading MC with circulating IgE has been pro-
posed to rapidly occur due to the formation of specific
cellular structures in MC that are able to penetrate the
endothelial cell layer of blood vessels [32]. On the other
hand, binding of IgE to the FcεRI receptor has been as-
sociated with an increase of MC cytokine synthesis and
MC survival [29,30], so, the observed increase on tumorgrowth could be due to the secretion of MC-derived in-
flammatory mediators or MC survival stimulated by IgE.
MC-derived VEGF seems to contribute to active angio-
genic processes observed in some tumors [15]. The effect
of IgE on tumor growth was sensitive to bevacizumab but
the obtained value was not statistically significant, sug-
gesting the participation of VEGF but also other com-
pounds on IgE actions. It has been shown that other
mediators such as tryptase released by mast cells play an
important role in neovascularization [33] and a close rela-
tionship has been demonstrated between tryptase-positive
MC and tumor vascularity in melanoma [14].
The positive influence of MC on tumor growth has been
demonstrated utilizing MC-deficient mice (KitWv/Wv) [23].
Our results with Wsh mice, a model used to study B16
melanoma growth and metastasis [34], confirm those find-
ings and extend the observation to include the participa-
tion of monomeric IgE as an important stimulus for MC
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pro-tumorigenic actions of MC.
Fyn kinase is an important effector of FcεRI signaling
system. Its activation after IgE/Antigen stimulation of
MC leads to degranulation, leukotriene synthesis and
selective cytokine expression [10,35]. However, its role
on monomeric IgE-mediated effects on MC seems to be
discrete, i.e. MC survival after IgE treatment requires
Lyn but not Fyn activation [36] and IgE-induced adhe-
sion to fibronectin was also shown to be independent of
Fyn [37]. Here we show for the first time that IgE-
induced VEGF synthesis requires Fyn activity, describ-
ing a non-recognized role of this kinase on IgE-induced
cytokine production.
Administration of tumor-specific mouse monoclonal
IgE antibodies prevent the development of mammary
adenocarcinoma [38] and inhibit colorectal carcinoma
growth [39]. Those and other studies have suggested
that IgE could exert a protective role against tumors









Figure 8 IgE improves the pro-angiogenic properties of MC through
FcεRI receptor on MC surface inducing the secretion of pro-angiogenic fac
tumor growth. Fyn kinase is an important element on IgE-dependent prodmice and our data support the idea that IgE is able to in-
duce pro-angiogenic factors that favour tumor growth.
Differences among our results and those obtained with
anti-tumor IgEs could be explained by the fact that SPE-
7 clone has been shown to be able to induce increased
cytokine synthesis in distinct MC preparations in vitro
[31]. Since it has been proposed that some allergic pa-
tients might produce cytokinergic IgE’s [11], our data
are relevant to the study of physiological conditions
where high plasmatic concentrations of non-specific IgEs
are reached, such as atopy [1].Conclusions
Our data suggest that monomeric IgE is able to potentiate
the pro-tumorigenic properties of MC in a Fyn kinase-
dependent fashion (Figure 8). Therefore, perturbing Fyn-
activated signaling pathways to inhibit MC-dependent
events leading to neovascularization of solid tumors




a Fyn kinase-dependent mechanism. Circulating IgE binds to the
tors able to promote tumor angiogenesis and contribute to melanoma
uction of pro-angiogenic factors in MC.
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Reagents
Salts, inhibitors and buffer components, as well as anti-
dinitrophenyl (DNP) IgE (clone SPE-7) and DNP coupled
to human serum albumin (DNP-HSA) were purchased
from Sigma-Aldrich. Recombinant IL-3 was purchased
from Peprotech.
Mice
C57BL/6J (wild type: WT; stock No. 000664), mast cell-
deficient B.6Cg-KitW-sh (Wsh; stock No. 005051), 129/
Sv-Lyntm1Sor/J (stock No. 003204) and 129-Fyntm1Sor/J
mice (stock No. 002271) were purchased from Jackson
Laboratories. 129-Fyntm1Sor/J mice were back-crossed
with C57BL/6J at least five times in our animal facilities
to obtain Fyn-deficient animals (Fyn −/−) on the C57BL/
6J genetic background. Genotyping of each animal was
performed by PCR from genomic DNA utilizing the
primers and conditions suggested by the provider. Ani-
mals were maintained under pathogen-free conditions
and treated in accordance with NIH guidelines. Experi-
ments were performed with age-matched male mice of
at least 8 weeks old and were approved by the animal
ethics committee of Cinvestav (CICUAL, protocol 032–
02 and 0478–10). When necessary, mice were eutha-
nized by CO2 inhalation.
Generation of bone marrow-derived mast cells
Bone marrow-derived mast cells (BMMCs) were gener-
ated extracting the bone marrow from both tibias of
mice four to eight weeks old. Bone marrow was cultured
in BMMC media (RPMI 1640 supplemented with 20 ng/mL
IL-3, 0.1 mM non-essential aminoacids, 50 μM β-
mercaptoethanol, 25 mM HEPES pH 7.4, 1mM pyru-
vate, antibiotic/antimycotic and 10% FBS) during four
weeks and after that, FcεRI receptor expression was ana-
lyzed by flow cytometry utilizing a specific positive for
the IgE receptor as described [41]. To confirm function-
ality of BMMC cultures, routinely two million of WT or
Fyn −/− BMMCs were incubated with 100 ng/ml of IgE
for 20 min in 1 ml of Tyrode’s-BSA buffer (20 mM
HEPES pH 7.4, 135 mM NaCl, 5 mM KCl 5 mM, 1.8 mM
CaCl2, 1 mMMgCl2, 5.6 mM glucose, 0.05% bovine serum
albumin; BSA) at 37°C. After incubation, different concen-
trations of the specific antigen (human serum albumin
coupled to DNP) were added. After 30 minutes at 37°C,
cell supernatants were collected and tested for β-hexosa-
minidase activity as described [15].
Cell stimulation with IgE and VEGF determination
Two million BMMCs were incubated with distinct con-
centrations of IgE for different times at 37°C in 1 ml of
BMMC media supplemented with a protease inhibitor
cocktail (mini-complete, Roche). VEGF was determinedin the supernatants utilizing ELISA kits from Peprotech
and Invitrogen. Actinomicyn D (Act D; 5 μg/ml),
Brefeldin A (BFA; 5 μg/ml), Tetanus toxin (TTx; 10 ng/ml)
and PP2 (10 μM) were added to the cells 15 min previous
to the stimulation [15,42] with 1000 ng/ml IgE for 8 h
at 37°C.
RNA extraction and RT-PCR
Two million BMMCs were incubated with 1000 ng/ml
IgE at 37°C for different times. Total RNA was isolated
utilizing Tri-Reagent and isopropanol RNA precipitation
as described [43]. cDNA synthesis was performed
starting with 5 μg of total RNA utilizing the Superscript
First Strand System for RT-PCR from Invitrogen, follow-
ing the instructions included. Reported primers were
used to amplify VEGF [44] and GAPDH [45], utilizing
one tenth of the cDNA reaction volume. Standardization
of the number of cycles needed to obtain linear amplifi-
cation of VEGF and GAPDH mRNAs in our samples
was performed experimentally. Linear amplification for
VEGF was obtained between 30 and 40 cycles, whereas
for GAPDH it was between 25 and 30 cycles. Then, con-
ditions for VEGF amplification were 94°C for 1.5 min;
35 cycles of 94°C for 30 sec, 58°C for 45 sec and 72°C
for 45 sec and additional extension at 72°C for 10 min.
Parameters for GAPDH amplification were the same but
only 28 cycles of amplification were used for this gene.
RT-PCR products were separated in 2% agarose gels.
Photographs of each gel were quantified utilizing the
LabWorks Image Acquisition and Analysis software
(v 4.5) installed in a UVP image analyzer.
Immunofluorescence
Two million BMMCs were incubated with 1000 ng/ml
IgE for 8 h in 2 ml of BMMC media supplemented with
a protease inhibitor cocktail (Roche) at 37°C. Cells were
collected by centrifugation using a cytospin, then
washed, fixed in cold acetone for 5 min at 4°C, washed
again and blocked with 3% BSA, 2% goat serum and
0.01% Tween-20 in PBS for 30 min at RT. Cells were in-
cubated with an anti-VEGF rabbit polyclonal serum
(1:50; sc-507, Santa Cruz) diluted in blocking solution
overnight at 4°C. After washes with PBS, slides were
treated with an Alexa 568-anti-goat secondary antibody
(1:500, Invitrogen) diluted in blocking solution for one
hour. Finally, an incubation with 4′, 6-diamidino-2-
phenylindole, dihydrochloride (DAPI, Invitrogen) for
5 min at RT was performed and slides were properly
mounted. A confocal microscope (Olympus FluoView
FV1000) with a 405-nm laser for DAPI and 543–nm
laser for Alexa 568 was used. Fluorophores were imaged
using a sequential line scan, with detection bands set at
405 to 461 nm for DAPI stain and 543 to 603 nm for
Alexa 568. Each image was saved at a resolution of
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escence intensities of VEGF per cell were measured
from 13 to 33 cells per experimental group utilizing the
software LabWorks 4.5.
Western blot
Two million BMMCs were incubated with 1000 ng/ml IgE
for 0, 15, 30 and 60 min in Tyrode’s buffer without BSA
[16] at 37° [46]. Cell pellets were isolated and lysed on
Laemmli 1X buffer. In general, fifty micrograms of total
MC protein was separated in SDS-PAGE and transferred
to PVDF to conduct western blot using reported solutions
and methods [41]. Antibodies against phospho-pS6 ribo-
somal protein (Ser 235/236, 1:1000) and phospho-4E-BP1
(Thr37/46, 1:1,000) were purchased to Cell Signaling
Technology. For loading control, membranes were incu-
bated with an anti-β-actin antibody (1:10,000) from Santa
Cruz. Densitometric analysis was performed utilizing
an Epichemi Darkroom from UVP Systems, with the
LabWorks 4.5 software.
Standardization of IgE dose to test its effects on tumor
growth
In order to evaluate the role of IgE on melanoma tumor
growth, we first determined the amount of IgE that
could be needed to occupy the free FcεRI receptor on
the surface of mast cells in vivo. C57BL/6J mice were i.v.
injected with saline solution or, 25, 50, 250, 500, 750 and
1000 ng of anti-DNP IgE dissolved in 100 μL of sterile
saline solution. Then, a passive anaphylaxis assay [25,26]
was performed by i.v administering 100 μg DNP-HSA in
100 μl Evans blue dye (0.25%). Twenty minutes later, an-
imals were euthanized and the limbs were removed. The
amount of extravased dye in the tissue was measured as
previously described [25,26]. To test the amount of free
IgE after administration, C57BL/6J mice were i.v.
injected with 0, 25, 50, 250, 500, 750 and 1000 ng of
anti-DNP IgE and trunk blood was collected 0, 1, 7, 14,
21 and 28 days later. Each blood sample was centrifuged
at 21,000 x g for 20 min at 4°C and the resultant serum
was stored at −80°C. IgE levels were determined utilizing
an ELISA kit (BD Biosciences).
Reconstitution of mast cell-deficient mice
MC-deficient (Wsh) mice (eight to twelve weeks old)
were reconstituted with MC as described [47]. Briefly,
mice were i.v. injected with BMMCs (2×106 cells) in
Tyrode’s buffer without BSA and four weeks after adop-
tive transfer of BMMCs MC reconstitution was con-
firmed by histological analysis of ear pinna and passive
cutaneous anaphylactic reactions. Wsh mice were
reconstituted with BMMCs obtained from C57BL/6J
(Wsh Rec WT) or C57BL/6J-Fyn−/− (Wsh Rec Fyn−/−)
mice. Animals were inoculated with melanoma cells fourto six weeks after reconstitution and tumor growth (see
following section) was compared with age-matched WT
and non-reconstituted animals.
B16 melanoma cell line culture and tumor generation
B16-F1 melanoma cells obtained from ATCC (CRL-6323;
low metastatic variant) were generously donated by
Dr. Guadalupe Reyes, Cinvestav, and cultured as suggested
by the provider. Briefly, cells were propagated in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
FBS, 100 U of penicillin and 100 μg/ml of streptomycin
[23]. For tumor generation, mice were s.c inoculated into
the left ear pinna with 0.5 × 106 B16 melanoma cells in
Tyrode’s buffer without BSA and the right ear pinna with
vehicle [23]. Tumor weight development was monitored
on daily basis and tumors were removed 28 days after in-
oculation to register weight differences between left and
right ear pinna. Normal development of the tumors was
routinely confirmed by histological analysis, where melan-
oma cells, blood vessel formation and infiltrating inflam-
matory cells were detected by specific dyes at different
times after inoculation [48]. To test the influence of IgE on
melanoma tumor growth, mice were i.v. administered with
IgE (750 ng) or vehicle 24 hours previous to melanoma cell
inoculation. When necessary, mice were treated with
bevacizumab 10 mg/kg s.c., biweekly, starting 24 h after
inoculation of melanoma cells (modified from [49]).
Histological analysis
Biopsy specimens of the ears inoculated with vehicle or
B16 melanoma cells were fixed in neutral buffered for-
malin (10% formaldehyde in 10 mM phosphate buffer
pH 7.0) prior to paraffin embedding. Sections of 2.5 μm
were cut and examined. For each treated animal (n = 2-7
per group), some ear sections were stained with
hematoxylin and eosin (H&E) and other sections were
stained with 0.1% toluidine blue (TB), pH 1.0 [50] in
order to analyze blood vessels and mast cells, respect-
ively. Ear pinna mast cells were counted by dividing the
whole pinna area in consecutive fields length extending
from the base to the tip (7.3–12.62 mm) under the 40X
objective. Mast cells numbers are expressed as mean ±
SEM per length of ear pinna. Images of histological sec-
tions were obtained with a microscope (Zeiss Axiostar)
coupled to a digital camera (Power Shot A640). For each
mouse, two sections were analyzed and counts were av-
eraged. Blood vessel quantification was performed on 15
high-powered images of randomly selected areas of each
paraffin section stained by H&E (x200). All histological
measurements were done by two observers on blinded
samples (control or tumor-bearing with or without IgE).
In sections stained by H&E, the absolute number of
large and small vessels per ear pinna was monitored by
morphological analysis according to Carmeliet, 2003, i.e.
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considered small vessels, whereas those with the smooth
muscle cell layer were considered to be large blood
vessels [51].
Statistical analysis
Unless specified otherwise, all data are expressed as the
mean ± SEM of at least three independent experiments.
Student’s t-test or Two-Way ANOVA followed by
Student-Newman Keuls test was used to evaluate the sig-
nificance of the differences. Statistically significant was set
at P < 0.05.
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